Picture of CytomX Therapeutics logo

CTMX CytomX Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapMomentum Trap

Annual cashflow statement for CytomX Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K/A10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-102-32.9-116-99.3-0.569
Depreciation
Amortisation
Non-Cash Items18.517.416.616.74.87
Other Non-Cash Items
Changes in Working Capital-59.318.1-22.4-30.7-62.5
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-1405.26-119-111-56
Capital Expenditures-3.5-2.31-1.61-1.74-0.84
Purchase of Fixed Assets
Other Investing Cash Flow Items83.2-16.424.1100-150
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities79.7-18.722.598.3-151
Financing Cash Flow Items0.648
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Cash from Financing Activities1.6316.91100.64830.2
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-59.23.4313.7-11.9-176